Dr Joan Merrill presents a phase 2 trial use of Iberdomide in patients with #SLE -Novel MOA —> blocks TF Ailos and Ikaros Conclusion -Primary end point was met at week 24 -Effects greater in Aiolos high/Type 2 IFN high -Iverdomdie was tolerated well #Lupus #ACR20 #ACRambassador https://t.co/zpQR9ceV7p